286 related articles for article (PubMed ID: 24857060)
1. Immunotherapy for glioma: from illusion to realistic prospects?
Dietrich PY; Dutoit V; Walker PR
Am Soc Clin Oncol Educ Book; 2014; ():51-9. PubMed ID: 24857060
[TBL] [Abstract][Full Text] [Related]
2. The value of EGFRvIII as the target for glioma vaccines.
Lowenstein PR; Castro MG
Am Soc Clin Oncol Educ Book; 2014; ():42-50. PubMed ID: 24857059
[TBL] [Abstract][Full Text] [Related]
3. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.
Chuntova P; Downey KM; Hegde B; Almeida ND; Okada H
Front Immunol; 2018; 9():3062. PubMed ID: 30740109
[TBL] [Abstract][Full Text] [Related]
4. Cellular immunotherapy for malignant gliomas.
Lin Y; Okada H
Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
[TBL] [Abstract][Full Text] [Related]
5. [Immunotherapy in brain tumors].
De Carli E; Delion M; Rousseau A
Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040
[TBL] [Abstract][Full Text] [Related]
6. Targeting EGFRvIII for glioblastoma multiforme.
Yang J; Yan J; Liu B
Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
[TBL] [Abstract][Full Text] [Related]
7. [Brain tumor immunotherapy: Illusion or hope?].
Migliorini D; Dutoit V; Walker PR; Dietrich PY
Bull Cancer; 2017 May; 104(5):476-484. PubMed ID: 28318492
[TBL] [Abstract][Full Text] [Related]
8. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
Ikeda H
Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
[TBL] [Abstract][Full Text] [Related]
9. Glioma antigen.
Toda M
Adv Exp Med Biol; 2012; 746():77-84. PubMed ID: 22639160
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of Brain Tumors.
Dutoit V; Migliorini D; Walker PR; Dietrich PY
Prog Tumor Res; 2015; 42():11-21. PubMed ID: 26376741
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy.
Yang P; Meng M; Zhou Q
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188558. PubMed ID: 33933558
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy: moving forward with peptide T cell vaccines.
Kumai T; Fan A; Harabuchi Y; Celis E
Curr Opin Immunol; 2017 Aug; 47():57-63. PubMed ID: 28734176
[TBL] [Abstract][Full Text] [Related]
13. Glioma-specific antigens for immune tumor therapy.
Skog J
Expert Rev Vaccines; 2006 Dec; 5(6):793-802. PubMed ID: 17184218
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes.
Qi Y; Liu B; Sun Q; Xiong X; Chen Q
Front Immunol; 2020; 11():578877. PubMed ID: 33329549
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy: a treatment for the masses.
Blattman JN; Greenberg PD
Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
[TBL] [Abstract][Full Text] [Related]
16. 70-kDa heat shock protein coated magnetic nanocarriers as a nanovaccine for induction of anti-tumor immune response in experimental glioma.
Shevtsov MA; Nikolaev BP; Yakovleva LY; Parr MA; Marchenko YY; Eliseev I; Yudenko A; Dobrodumov AV; Zlobina O; Zhakhov A; Ischenko AM; Pitkin E; Multhoff G
J Control Release; 2015 Dec; 220(Pt A):329-340. PubMed ID: 26522072
[TBL] [Abstract][Full Text] [Related]
17. T11TS immunotherapy repairs PI3K-AKT signaling in T-cells: Clues toward enhanced T-cell survival in rat glioma model.
Chaudhuri S; Singh MK; Bhattacharya D; Datta A; Hazra I; Mondal S; Faruk Sk Md O; Ronsard L; Ghosh TK; Chaudhuri S
J Cell Physiol; 2018 Feb; 233(2):759-770. PubMed ID: 28608562
[TBL] [Abstract][Full Text] [Related]
18. Antigen-receptor gene-modified T cells for treatment of glioma.
Ikeda H; Shiku H
Adv Exp Med Biol; 2012; 746():202-15. PubMed ID: 22639170
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
[TBL] [Abstract][Full Text] [Related]
20. Novel chemotherapeutics and other therapies for treating high-grade glioma.
Kang JH; Adamson C
Expert Opin Investig Drugs; 2015; 24(10):1361-79. PubMed ID: 26289791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
